|
|
Article: Strong results for ALK-Abello's Grazax.(allergy vaccinations)(Brief Article)
- Article from:
- Pharma Marketletter
- Article date:
- November 14, 2005
CopyrightCOPYRIGHT 2005 Marketletter Publications Ltd. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Denmark-based ALK-Abello, a leading developer of allergy vaccinations in Europe, says that clinical data on Grazax, its oral immunotherapy for grass pollen allergies, show that it reduces the symptoms of hay fever 30% and also causes a 38% drop in the need for symptom-relieving medication.
The 634-patient GT-08 study confirmed the optimal dose of 75,000 SQ-T and also found that patients on the tablets experienced an improved quality of life.
...